Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 2/20 | 0.34 |
| ▸ | METTL3 | Q86U44 | 9/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 4/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31617962 | 0.90 | METTL3 (0.38) | METTL3PRMT5WDR77 | |
| SCHEMBL30941588 | 0.85 | ALDH1A1 (0.33) | ALDH1A1NT5EACACBACACASRC | |
| SCHEMBL31617928 | 0.84 | NT5E (0.32) | NT5EMETTL3PRMT5WDR77 | |
| SCHEMBL25048952 | 0.83 | SRC (0.37) | NT5EMETTL3PRMT5WDR77SRC | |
| SCHEMBL30940722 | 0.83 | SRC (0.37) | NT5EMETTL3PRMT5WDR77SRC | |
| SCHEMBL25048253 | 0.82 | ADORA2A (0.30) | — | |
| SCHEMBL30940981 | 0.82 | ADORA2A (0.30) | — | |
| SCHEMBL30941177 | 0.80 | ADK (0.33) | — | |
| SCHEMBL25048894 | 0.76 | METTL3 (0.39) | METTL3PRMT5WDR77CA2SRC | |
| SCHEMBL25047701 | 0.76 | ACACB (0.31) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | ALDH1A1 2233/4885NT5E 2836/4885METTL3 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.